Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade)

Amgen was upgraded to buy after a Q2 growth rebound in which 22 products delivered at least double-digit sales growth, led by accelerating Tezspire and Repatha. Despite cost-of-sales pressure, profitability remained solid and Amgen raised its full-year 2026 revenue and EPS guidance, reinforcing confidence in its long-term growth outlook.

Analysis

The investable question is whether Amgen’s growth is broad enough to offset the remaining erosion in mature franchises and the earnings drag from a higher fixed-cost base. Tezspire is economically more valuable than its reported sales alone because it validates Amgen’s inflammation platform and creates a higher-quality growth mix, while Repatha’s trajectory is sensitive to payer access and cardiovascular prevention guidelines rather than simply prescription growth. The near-term multiple response should depend on whether the guidance increase is driven by durable volume, pricing, or nonrecurring expense timing; only the first two justify a sustained rerating.

Over the next 1-3 months, consensus estimates are likely to move higher if management’s raised outlook is supported by continued acceleration in the named growth brands and stable gross margin. The main offset is that cost-of-sales pressure can become more consequential as biosimilar competition reduces the contribution from high-margin legacy products; incremental revenue will not translate one-for-one into EPS if launch, manufacturing, and acquisition-related costs remain elevated. A more important 6-18 month catalyst is clinical and commercial de-risking of the obesity pipeline: success would create a new earnings-duration narrative, while disappointing efficacy, tolerability, or differentiation would leave AMGN valued primarily as a mature large-cap biopharma.

The contrarian view is that a favorable rating change may overstate the immediacy of the earnings inflection. Broad double-digit product growth is not necessarily material if the largest revenue pools remain under pressure, and Tezspire economics are shared with AstraZeneca. AMGN should outperform only if estimate revisions continue after the initial guidance reset; otherwise, the stock may remain range-bound as investors discount pipeline optionality but demand clearer evidence of margin expansion and debt reduction.

Key Decisions for Investors

• Initiate a measured long AMGN position on post-upgrade weakness rather than chase the initial move; use the next earnings report as the 1-3 month catalyst. Target a 8-12% upside from multiple expansion plus estimate revisions, with thesis invalidated by a guidance cut or evidence that the outlook increase is primarily below-the-line or timing-related.
• Prefer a relative-value trade of long AMGN / short PFE over an outright broad-biotech long for the next quarter: Amgen has better identifiable commercial growth drivers, while Pfizer remains more exposed to resetting post-COVID earnings expectations. Exit if AMGN’s next-quarter product-growth commentary weakens or PFE delivers a material pipeline/earnings surprise.
• Monitor Tezspire and Repatha prescription-growth disclosures, gross-margin guidance, and net-debt reduction at the next results. If growth-brand momentum remains intact but gross margin falls further, reduce the position: that combination would signal revenue growth is not converting into the EPS durability required for rerating.
• Do not add obesity-pipeline upside to base-case valuation until efficacy, discontinuation, and competitive-positioning data are independently validated. A positive clinical update would be an alert for adding long exposure; a weak data set would favor trimming AMGN even if near-term marketed-product execution remains solid.